AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03149991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: administration 6 times over two weeks of inhaled ketamine
Study NCT00438477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99m sulfur colloid
Description: At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection.
Study NCT03861793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALKS 4230
Description: SC injection administered in the back of the arm or the abdomen
Study NCT03861793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion over 30 minutes
Study NCT03149991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: administration 6 times over two weeks of inhaled ketamine
Study NCT03149991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo which matches brexpiprazole in size and number of tablets per dose
Study NCT03096847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
Study NCT03096847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
Study NCT03096847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Premenopausal patients additionally received goserelin 3.6mg as monthly implant
Study NCT02412150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia is maintained with desflurane
Study NCT02412150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desflurane
Description: Anesthesia is maintained with desflurane
Study NCT02412150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
Study NCT02412150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
Study NCT02412150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Description: The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
Study NCT00633750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matrix-assisted laser desorption ionization mass spectrometry
Description: After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
Study NCT00633750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgical treatment will occur within 24-hours following completion of therapy.
Study NCT01471678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg)
Description: This study is an open-label, randomized, single dose, four-period cross-over study.
Study NCT01471678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)
Description: FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
Study NCT01471678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)
Description: a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
Study NCT04121975 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
Study NCT04121975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
Study NCT04121975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
Study NCT01686308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yellow Intra Ocular Lens (IOL)
Description: Standard operation with blue light filter Yellow IOL implantation
Study NCT01686308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Intra Ocular Lens (IOL)
Description: Standard operation with conventional IOL implantation
Study NCT00334958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
Study NCT00906529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levemir (Detemir) and Novolog (Aspart) Insulin
Description: Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
Study NCT01869946 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine
Study NCT02979808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navina Smart
Description: Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
Study NCT00869011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
Study NCT00117936 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose
Description: Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
Study NCT00117936 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
Description: Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
Study NCT00117936 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
Study NCT05283447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Medicine
Description: The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
Study NCT05283447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
Study NCT02146716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energetic Resonance by Cutaneous Stimulation
Description: Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
Study NCT01444417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
Study NCT01444417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by subcutaneous injection
Study NCT01836133 — intervention group
Intervention type: DRUG
Intervention: Erlotinib 150 mg
Study NCT03107546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalomatrix
Description: We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
Study NCT03107546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin graft
Description: We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
Study NCT03072199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection
Description: Single dose of Rituximab given intravenously within 48hours of myocardial infarction
Study NCT02159170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGF injection
Description: single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
Study NCT03968198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous ASC (for Adipose-derived Stem/Stroma Cell)
Description: After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
Study NCT03585465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: * Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~* Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C
Study NCT03585465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: * Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C
Study NCT03585465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: * Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C
Study NCT03585465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Arm A, B or C (First stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle~* Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle
Study NCT02274207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT application
Description: NPWT mode is cyclic mode : -125\~-50 mmHg
Study NCT02274207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT application
Description: NPWT mode is cyclic mode : -125\~-50 mmHg
Study NCT01300923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Study NCT01440439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
Study NCT01440439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
Study NCT02041936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife IRE System
Study NCT01714375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QuietDose Device
Description: The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss.
Study NCT01698775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
Study NCT01698775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Matching placebo to omarigliptin capsule administered orally once a week
Study NCT01698775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
Study NCT01698775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
Study NCT01698775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glipizide
Description: Matching placebo to glipizide daily
Study NCT01698775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to glipizide
Description: Matching placebo to glipizide daily
Study NCT01698775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
Study NCT01698775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
Study NCT01372241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay health advisor visits and newsletter
Description: The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
Study NCT06456619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth restoration
Description: Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
Study NCT06456619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth restoration
Description: Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
Study NCT01946776 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: implantable heart rate monitor
Description: Implantation of Reveal XT
Study NCT03977974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally
Study NCT03977974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01736436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with APG101
Description: Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
Study NCT01736436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow collection
Description: During the study, bone marrow will be collected 4 times to assess study objectives
Study NCT01736436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood drawings
Description: During the study, blood will be drawn at different time points to assess study objectives
Study NCT02428686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta (NeoRecormon)
Description: Epoetin beta 60 000 IU/week
Study NCT01775969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: A text message with instructions is sent to the patient
Study NCT01775969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voicemail
Description: A voicemail with instructions is sent to the patient
Study NCT00767338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Timed intercourse
Description: Timed intercourse
Study NCT00767338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microsurgical varicocelectomy
Description: Microsurgical varicocelectomy
Study NCT02412150 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thyroidectomy
Description: The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed.
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vital signs
Description: Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed.
Study NCT02412150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cough reflex
Description: During recovery from anesthesia at operation room, cough reflex is measured and rated. \[Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)\]
Study NCT02412150 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cough reflex
Description: During recovery from anesthesia at operation room, cough reflex is measured and rated. \[Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)\]
Study NCT02412150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ramsay Sedation Scale
Description: When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~1. Awake Patient anxious and agitated or restless or both!~2. Patient cooperative, oriented and tranquil!~3. Patient responds to commands only!~4. Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~5. A sluggish response to a light glabellar tap or loud auditory stimulus!~6. No response to a light glabellar tap or loud auditory stimulus